Oculis Holding AG (OCS) Financial Ratios
5 years of historical data (2020–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
13.35
↑+106% vs avg
5yr avg: 6.47
30Y Low3.6·High9.4
ROE
↓
-102.7%
-4% vs avg
5yr avg: -98.7%
30Y Low-103%·High-95%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
OCS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Oculis Holding AG currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $1.8B | $687M | $336M | $331M | $317M | — |
| Enterprise Value | $1.8B | $660M | $298M | $434M | $385M | — |
| P/E Ratio → | -11.44 | — | — | — | — | — |
| P/S Ratio | 2043.12 | 1001.34 | — | — | — | — |
| P/B Ratio | 13.35 | 9.36 | 3.58 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
OCS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 962.67 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
OCS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Oculis Holding AG earns an operating margin of -10671.1%. A negative ROE of -102.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | -7492.3% | -7492.3% | — | — | — | — |
| Operating Margin | -10671.1% | -10671.1% | — | — | — | — |
| Net Profit Margin | -12503.9% | -12503.9% | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -102.7% | -102.7% | -94.7% | — | — | — |
| ROA | -73.1% | -73.1% | -117.3% | -81.4% | -49.9% | -90.8% |
| ROIC | -106.8% | -106.8% | -197.5% | -393.4% | -149.9% | -149.1% |
| ROCE | -85.4% | -85.4% | -134.2% | -81.9% | -40.1% | -102.5% |
OCS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $28M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.36 | -0.40 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | -55.16 | -5.03 | -2.58 | -4.69 |
Net cash position: cash ($28M) exceeds total debt ($1M)
OCS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Oculis Holding AG's current ratio of 2.37x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.97x to 2.37x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 2.37 | 2.37 | 5.29 | 1.97 | 11.81 | 1.42 |
| Quick Ratio | 2.37 | 2.37 | 5.29 | 1.97 | 11.81 | 1.42 |
| Cash Ratio | 2.23 | 2.23 | 4.80 | 1.65 | 11.39 | 1.14 |
| Asset Turnover | — | 0.01 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | 413.42 | — | — | — | — |
OCS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Oculis Holding AG does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $40M | $30M | $33M | $33M | $33M |
Peer Comparison
Compare OCS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 OCSYou | $2B | -11.4 | — | — | -7492.3% | -10671.1% | -102.7% | -106.8% | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 KALA | $617676 | -0.0 | — | — | — | — | -388.3% | — | — |
 LENZ | $278M | -3.4 | — | — | 97.8% | -477.5% | -33.6% | -30.7% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ALDX | $104M | -1.8 | — | — | — | — | -58.5% | -369.4% | — |
 REPL | $266M | -1.1 | — | — | — | — | -62.6% | -51.9% | — |
 AEYE | $100M | -32.4 | — | — | 78.3% | -7.9% | -43.2% | -42.4% | — |
 BHVN | $1B | -1.4 | — | — | — | — | -310.8% | -242.1% | — |
 EW | $48B | 45.2 | 25.4 | 35.7 | 78.1% | 27.0% | 10.5% | 15.5% | 0.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See OCS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OCS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OCS vs RCKT
Side-by-side business, growth, and profitability comparison vs Rocket Pharmaceuticals, Inc..
Start ComparisonOCS — Frequently Asked Questions
Quick answers to the most common questions about buying OCS stock.
What is Oculis Holding AG's P/E ratio?
Oculis Holding AG's current P/E ratio is -11.4x. This places it at the 50th percentile of its historical range.
What is Oculis Holding AG's ROE?
Oculis Holding AG's return on equity (ROE) is -102.7%. The historical average is -98.7%.
Is OCS stock overvalued?
Based on historical data, Oculis Holding AG is trading at a P/E of -11.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Oculis Holding AG's profit margins?
Oculis Holding AG has -7492.3% gross margin and -10671.1% operating margin.